Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients Drug discovery research coll...
The International Myeloma Foundation (IMF), which leads the Coalition to Improve Access to Cancer Care (CIACC), fervently supports the Cancer Drug Parity A...
“We’re seeing increased demand for Parse’s Evercode single cell sequencing solutions across Asia, and we believe our products are poised ...
BioPhy launched its AI operating system that radically accelerates the identification and development of the most promising drug candidates. By combi...
Both of these biomarkers are included in the company’s commercially available Precivity™ blood tests, which help healthcare providers determine...
“The first patient dosed with an AdvanCell therapeutic candidate represents a major milestone for the Company, our scientists, clinical trial sites, ...
Product Sales Excluding Veklury Increased 5% Year-Over-Year to $6.4 billion Biktarvy Sales Increased 12% Year-Over-Year to $3.1 billion Oncology Sales In...
-Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, an...
1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia. Top-line results for on-going, 52-week...
QIAGEN announced the launch of the Microbiome WGS SeqSets, a comprehensive Sample to Insight workflow designed to provide an easy-to-use solution that maxi...
Phase II results demonstrated significant albuminuria reductions by up to 39.5% vs. placebo when BI 690517, a novel selective aldosterone synthase inhibi...
Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a new generation of its distributed liquid bi...
Under the terms of the option agreement, AbbVie has the option to acquire a co-exclusive license to develop, manufacture, and commercialize reproxalap in t...
Initial EVX-01 Phase 2 data confirms the strong Phase 1 results After undergoing EVX-01 treatment, a significant and continuous tumor reduction was ...
© 2025 Biopharma Boardroom. All Rights Reserved.
